Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging

NeuroImage

Volumn 55, Issue 4, 2011, Pages 1600-1609

  Yang, Jing ^a   Zaim Wadghiri, Youssef ^a   Minh Hoang, Dung ^a   Tsui, Wai ^a   Sun, Yanjie ^a   Chung, Erika ^a   Li, Yongsheng ^a   Wang, Andrew ^c   de Leon, Mony ^a,b   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c OCEAN NANOTECH LLC   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Amyloid plaques; Magnetic resonance microimaging; Ultrasmall superparamagnetic iron oxide nanoparticles (USPIO); Voxel based morphometry

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; CONTRAST MEDIUM; MANNITOL; NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; HISTOPATHOLOGY; IN VIVO STUDY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE; VOXEL BASED MORPHOMETRY; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CONTRAST MEDIA; DEXTRANS; DRUG DELIVERY SYSTEMS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79952670561     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.01.023     Document Type: Article

References (61)

1. Anthony D.C., Sibson N.R., McAteer M.A., Davis B., Choudhury R.P. Detection of brain pathology by magnetic resonance imaging of iron oxide micro-particles. Methods Mol. Biol. 2011, 686:213-227.
2. Ashburner J. Computational anatomy with the SPM software. Magn. Reson. Imaging 2009, 27:1163-1174.
3. Ashburner J., Friston K.J. Voxel-based morphometry- the methods. Neuroimage 2000, 11:805-821.
4. Benveniste H., Einstein G., Kim K.R., Hulette C., Johnson G.A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:14079-14084.
5. Bernd H., De K.E., Gaillard S., Bonnemain B. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest. Radiol. 2009, 44:336-342.
6. Bharadwaj P.R., Dubey A.K., Masters C.L., Martins R.N., Macreadie I.G. Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 2009, 13:412-421.
7. Borthakur A., Gur T., Wheaton A.J., Corbo M., Trojanowski J.Q., Lee V.M., Reddy R. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J. Magn. Reson. Imaging 2006, 24:1011-1017.
8. Braakman N., Matysik J., Van Duinen S.G., Verbeek F., Schliebs R., de Groot H.J., Alia A. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 2006, 24:530-536.
9. Castillo L.B., Bugedo G.A., Paranhos J.L. Mannitol or hypertonic saline for intracranial hypertension? A point of view. Crit. Care Resusc. 2009, 11:151-154.
10. Chamberlain R., Reyes D., Curran G.L., Marjanska M., Wengenack T.M., Poduslo J.F., Garwood M., Jack C.R. Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magn. Reson. Med. 2009, 61:1158-1164.
11. Delatour B., Guegan M., Volk A., Dhenain M. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol. Aging 2006, 27:835-847.
12. Doran S.E., Ren X.D., Betz A.L., Pagel M.A., Neuwelt E.A., Roessler B.J., Davidson B.L. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery 1995, 36:965-970.
13. Dubois A., Herard A.S., Flandin G., Duchesnay E., Besret L., Frouin V., Hantraye P., Bonvento G., Delzescaux T. Quantitative validation of voxel-wise statistical analyses of autoradiographic rat brain volumes: application to unilateral visual stimulation. Neuroimage 2008, 40:482-494.
14. Dubois A., Herard A.S., Delatour B., Hantraye P., Bonvento G., Dhenain M., Delzescaux T. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage 2010, 51:586-598.
15. El Tannir El T.N., Delatour B., Le C.C., Guegan M., Volk A., Dhenain M. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2006, 22:199-208.
16. Falangola M.F., Dyakin V.V., Lee S.P., Bogart A., Babb J.S., Duff K., Nixon R., Helpern J.A. Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease. NMR Biomed. 2007, 20:343-351.
17. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2001, Academic Press, London.
18. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31:7748-7757.
19. Golabek A.A., Soto C., Vogel T., Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J. Biol. Chem. 1996, 271:10602-10606.
20. Gordon M.N., Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.W., Connor K., Melachrino J., O'Callaghan J.P., Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp. Neurol. 2002, 173:183-195.
21. Gumerlock M.K., Belshe B.D., Madsen R., Watts C. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J. Neurooncol. 1992, 12:33-46.
22. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
23. Helpern J., Lee S.P., Falangola M.F., Dyankin V., Bogart A., Ardekani B., Duff K., Branch C., Wisniewski T., De Leon M.J., Wolf O., O'Shea J., Nixon R. Magnetic Resonance imaging assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn. Reson. Med. 2004, 51:794-798.
24. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Saad W.K., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
25. Huang R., Ke W., Han L., Liu Y., Shao K., Jiang C., Pei Y. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res. Bull. 2010, 81:600-604.
26. Huddleston D.E., Small S.A. Technology insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. Nat. Clin. Pract. Neurol. 2005, 1:96-105.
27. Jack C.R., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., Adriany G., Grohn O.H.J., Grimm R., Poduslo J.F. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004, 52:1263-1271.
28. Larbanoix L., Burtea C., Laurent S., Van L.F., Toubeau G., Vander E.L., Muller R.N. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol. Aging 2010, 31:1679-1689.
29. Lee S.P., Falangola M.F., Nixon R.A., Duff K., Helpern J.A. Visualization of β-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn. Reson. Med. 2004, 52:538-544.
30. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev. Neurol. 2010, 6:108-119.
31. Manaye K.F., Wang P.C., O'Neil J.N., Huang S.Y., Xu T., Lei D.L., Tizabi Y., Ottinger M.A., Ingram D.K., Mouton P.R. Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry. Age 2007, 29:87-96. (Dordr.).
32. McAteer M.A., Choudhury R.P. Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. Prog. Brain Res. 2009, 180:72-96.
33. McCarty D.M., Dirosario J., Gulaid K., Muenzer J., Fu H. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther. 2009, 16:1340-1352.
34. Meadowcroft M.D., Connor J.R., Smith M.B., Yang Q.X. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 2009, 29:997-1007.
35. Neuwelt E.A., Barnett P.A., Hellstrom K.E., Hellstrom I., McCormick C.I., Ramsey F.L. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J. Nucl. Med. 1994, 35:1831-1841.
36. Nieman B.J., Szulc K.U., Turnbull D.H. Three-dimensional, in vivo MRI with self-gating and image coregistration in the mouse. Magn. Reson. Med. 2009, 61:1148-1157.
37. Nordberg A., Rinne J.O., Kadir A., Langstrom B. The use of PET in Alzheimer disease. Nat. Rev. Neurol 2010, 6:78-87.
38. Perl D.P. Neuropathology of Alzheimer's disease. Mt.Sinai. J. Med. 2010, 77:32-42.
39. Pike C.J., Walencewicz A.J., Glabe C., Cotman C. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991, 563:311-314.
40. Rabinovici G.D., Jagust W.J. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol. 2009, 21:117-128.
41. Rafii M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
42. Rapoport S.I. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol. 2000, 20:217-230.
43. Sadowski M., Pankiewicz J., Scholtzova H., Ripellino J.A., Li Y., Schmidt S.D., Mathews P., Fryer J.D., Holtzman D.M., Sigurdsson E.M., Wisniewski T. Blocking the apolipoprotein E/ß-amyloid interaction reduces β-amyloid toxicity and decreases β-amyloid load in transgenic mice. Am. J. Pathol. 2004, 165:937-948.
44. Sawiak S.J., Wood N.I., Williams G.B., Morton A.J., Carpenter T.A. Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol. Dis. 2009, 33:20-27.
45. Scholtzova H., Wadghiri Y.Z., Douadi M., Sigurdsson E.M., Li Y., Quartermain D., Banerjee P., Wisniewski T. A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown by micro-magnetic resonance imaging. J. Neurosci. Res. 2008, 86:2784-2791.
46. Sigurdsson E.M., Scholtzova H., Mehta P., Frangione B., Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol. 2001, 159:439-447.
47. Sigurdsson E.M., Wadghiri Y.Z., Sadowski M., Elliot J.I., Li Y., Scholtzova H., Tang C.Y., Aguilanldo J.G., Pappolla M., Duff K., Wisniewski T. In vivo magnetic resonance of amyloid plaques in Alzheimer's disease model mice. The Living Brain and Alzheimer's disease 2004, Springer-Verlag, Berlin. B. Hyman (Ed.).
48. Sigurdsson E.M., Wadghiri Y.Z., Mosconi L., Blind J.A., Knudsen E., Asuni A., Tsui W.H., Sadowski M., Turnbull D., de Leon M., Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 2008, 29:836-877.
49. Stoll G., Bendszus M. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience 2009, 158:1151-1160.
50. Takeuchi A., Irizarry M.C., Duff K., Saido T., Hsiao Ashe K., Hasegawa H., Mann D.M., Hyman B.T., Iwatsubo T. Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 2000, 157:331-339.
51. Tang M.E., Lobel D.A. Severe traumatic brain injury: maximizing outcomes. Mt. Sinai J. Med. 2009, 76:119-128.
52. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
53. Vanhoutte G., Dewachter I., Borghgraef P., Van L.F., Vander L.A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 2005, 53:607-613.
54. Wadghiri Y.Z., Sigurdsson E.M., Sadowski M., Elliot J.I., Li Q., Scholtzova H., Tang C.Y., Aguinaldo J.G., Pappolla M., Duff K., Turnbull D., Wisniewski T. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance micro-imaging. Magn. Reson. Med. 2003, 50:293-302.
55. Wadghiri Y.Z., Sigurdsson E.M., Wisniewski T., Turnbull D. MR Imaging of amyloid plaques in transgenic mice. Amyloid proteins: methods and protocols 2005, 365-379. Humana Press Inc., Totowa, NJ. E.M. Sigurdsson (Ed.).
56. Weinstein J.S., Varallyay C.G., Dosa E., Gahramanov S., Hamilton B., Rooney W.D., Muldoon L.L., Neuwelt E.A. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab. 2010, 30:15-35.
57. Weissleder R., Elizondo G., Wittenberg J., Lee A.S., Josephson L., Brady T.J. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990, 175:494-498.
58. Wimo A., Prince M. World Alzheimer Report 2010: the global economic impact of dementia 2010, Alzheimer's Disease International.
59. Wisniewski T., Boutajangout A. Vaccination as a therapeutic approach for Alzheimer's disease. Mt. Sinai J. Med. 2010, 77:17-31.
60. Yasuhara T., Hara K., Maki M., Xu L., Yu G., Ali M.M., Masuda T., Yu S.J., Bae E.K., Hayashi T., Matsukawa N., Kaneko Y., Kuzmin-Nichols N., Ellovitch S., Cruz E.L., Klasko S.K., Sanberg C.D., Sanberg P.R., Borlongan C.V. Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts. J. Cell. Mol. Med. 2010, 14:914-921.
61. Zaim Wadghiri Y., Sigurdsson E.M., Sadowski M., Tang C.Y., Aguilanldo J.G., Elliot J.I., Li Y., Pappolla M.A., Duff K., Turnbull D., Wisniewski T. Detection of Alzheimer's amyloid lesions in transgenic mice by magnetic resonance imaging. Magn. Reson. Med. 2003, 50:293-302.